Med Life And 2 Top Insider-Owned Growth Stocks

As global markets navigate a landscape marked by interest rate adjustments and fluctuating economic indicators, the U.S. indices have shown resilience with notable performances in sectors like utilities and real estate. Against this backdrop, investors often look for growth companies with high insider ownership, as these firms can offer unique insights into potential long-term value creation driven by those who know the business best.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	11.9%	21.1%
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	27.4%
KebNi (OM:KEBNI B)	36.3%	87.2%
Findi (ASX:FND)	35.8%	64.8%
HANA Micron (KOSDAQ:A067310)	18.3%	105.8%
Pharma Mar (BME:PHM)	11.8%	55.1%
Adveritas (ASX:AV1)	21.2%	144.2%
Plenti Group (ASX:PLT)	12.8%	107.6%
EHang Holdings (NasdaqGM:EH)	32.8%	81.4%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.9%	95%

Click here to see the full list of 1495 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Med Life (BVB:M)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Med Life S.A. is a private healthcare provider offering services across several Romanian cities, with a market cap of RON3.10 billion.

Operations: The company's revenue is primarily derived from its Clinics segment at RON921.64 million, followed by Hospitals at RON567.97 million, Corporate services at RON289.25 million, Laboratories at RON263.48 million, Dentistry services totaling RON125.18 million, and Pharmacies contributing RON61.82 million.

Insider Ownership: 39.3%

Revenue Growth Forecast: 11.6% p.a.

Med Life's recent financial performance shows robust growth, with revenue rising to RON 1.31 billion and net income increasing to RON 20.41 million for the half year ended June 2024. Despite trading significantly below its estimated fair value, the company's earnings are forecasted to grow substantially at 83% annually, outpacing market averages. However, its return on equity is expected to remain low in three years and interest payments are not well covered by earnings.

• Click here to discover the nuances of Med Life with our detailed analytical future growth report.
• Upon reviewing our latest valuation report, Med Life's share price might be too pessimistic.

Shanghai Sanyou Medical (SHSE:688085)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shanghai Sanyou Medical Co., Ltd. is engaged in the research, development, manufacturing, and sale of orthopedic implants in China with a market cap of CN¥4.94 billion.

Operations: Shanghai Sanyou Medical Co., Ltd. generates revenue primarily from its operations in the research, development, manufacturing, and sale of orthopedic implants within China.

Insider Ownership: 28.6%

Revenue Growth Forecast: 29.3% p.a.

Shanghai Sanyou Medical's recent earnings reveal a challenging period, with revenue and net income declining significantly compared to the previous year. Despite this, the company is poised for strong growth, with earnings expected to increase by 44.8% annually over the next three years, surpassing market averages. Revenue growth is also projected at 29.3% per year. However, profit margins have decreased considerably from last year and return on equity remains low in future forecasts.

• Navigate through the intricacies of Shanghai Sanyou Medical with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that Shanghai Sanyou Medical's current price could be inflated.

Chongqing Mas Sci.&Tech.Co.Ltd (SZSE:300275)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Chongqing Mas Sci.&Tech.Co.,Ltd. operates in China, offering safety technology equipment and safety information services, with a market capitalization of approximately CN¥3.70 billion.

Operations: The company's revenue segments include safety technology equipment and safety information services, with reported figures in millions of CN¥.

Insider Ownership: 21.8%

Revenue Growth Forecast: 23.5% p.a.

Chongqing Mas Sci.&Tech.Co.Ltd. demonstrates strong growth potential with earnings expected to rise 30.5% annually, outpacing the Chinese market average of 23.8%. Revenue is also forecasted to grow significantly at 23.5% per year. Despite a volatile share price recently, the company has engaged in a share buyback program, repurchasing shares worth CNY 25.5 million since February 2024, indicating confidence in its future prospects without substantial insider trading activity reported recently.

• Take a closer look at Chongqing Mas Sci.&Tech.Co.Ltd's potential here in our earnings growth report.
• Our expertly prepared valuation report Chongqing Mas Sci.&Tech.Co.Ltd implies its share price may be too high.

Turning Ideas Into Actions

• Reveal the 1495 hidden gems among our Fast Growing Companies With High Insider Ownership screener with a single click here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com